Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides-Reference-Cited by-同舟云学术

Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides

Published:2020-01-17 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Mamedov Azad,Vorobyeva Nadezhda,Filimonova Ioanna,Zakharova Maria,Kiselev Ivan,Bashinskaya Vitalina,Baulina Natalia,Boyko Alexey,Favorov Alexander,Kulakova Olga,Ziganshin Rustam,Smirnov Ivan,Poroshina Alina,Shilovskiy Igor,Khaitov Musa,Sykulev Yuri,Favorova Olga,Vlassov Valentin,Gabibov Alexander,Belogurov Alexey

Funder

Russian Science Foundation

Russian Foundation for Basic Research

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference45 articles.

1. A molecular basis for MHC class II–associated autoimmunity;Todd;Science.,1988

2. MHC class-II molecules and autoimmunity;Nepom;Annu Rev Immunol.,1991

3. HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance;Seliger;Oncoimmunology.,2017

4. HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition;Prentice;Sci Transl Med.,2015

5. T-cell-antigen recognition and the immunological synapse;Huppa;Nat Rev Immunol.,2003

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics;International Journal of Molecular Sciences;2024-07-04

2. Antigenic Peptide-Thioredoxin Fusion Chimeras for In Vitro Stimulus of CD4+ TCR+ Jurkat T Cells;Doklady Biochemistry and Biophysics;2024-05-03

3. Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis;Clinical Immunology;2023-12

4. MHC Class II Presentation in Autoimmunity;Cells;2023-01-14

5. Autoimmunerkrankungen;Reproduktionsimmunologie;2023